Ignite Creation Date:
2024-05-06 @ 4:01 PM
Last Modification Date:
2024-10-26 @ 2:02 PM
Study NCT ID:
NCT04849273
Status:
TERMINATED
Last Update Posted:
2023-05-26
First Post:
2021-04-12
Brief Title:
A Study of TPX-0131 a Novel Oral ALK Tyrosine Kinase Inhibitor in Patients With ALK Advanced or Metastatic NSCLC
Sponsor:
Turning Point Therapeutics Inc
Organization:
Turning Point Therapeutics Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Non Small Cell Lung Cancer |
| Non-Small Cell Lung Cancer |
| NSCLC |
| Advanced Solid Tumor |
| Metastatic Solid Tumor |
| ALK Gene Mutation |
Keywords:
| Name | View |
|---|---|
| ALK Tyrosine Kinase Inhibitor | View |
| Non Small Cell Lung Cancer | View |
| Non-Small Cell Lung Cancer | View |
| NSCLC | View |
| Advanced Non-Small Cell Lung Cancer | View |
| Advancedmetastatic disease | View |
| Lung cancer | View |
| Metastatic solid tumor | View |
| Advanced solid tumor | View |
| ALK gene fusion | View |
| ALK inhibitor | View |
| TPX-0131 | View |
| ALK TKI | View |